**Xilio Therapeutics Reports Financial Results and Operational Progress in 2025**

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, reported its financial results for the year ended December 31, 2025. The company's collaboration and license revenue increased significantly to $43.8 million, compared to $6.3 million in 2024. This increase was primarily attributed to revenue recognized under the collaboration, license, and option agreement with AbbVie, as well as increased revenue recognized under the license agreement with Gilead, including a $7.0 million cumulative catch-up related to a development milestone.

The company's research and development expenses also increased, reaching $56.0 million in 2025 compared to $41.2 million in the previous year. This rise was mainly due to the advancement of XTX501 into IND-enabling studies, increased clinical development activities for efarindodekin alfa, and higher external expenses related to preclinical research and development, including costs associated with the AbbVie collaboration. These increases were partially offset by decreased clinical development activities for XTX202. General and administrative expenses also saw an increase, rising to $29.7 million from $24.8 million, driven by higher personnel-related costs and professional and consulting fees.

Xilio Therapeutics reported a net loss of $35.0 million for 2025, a decrease from the $58.2 million net loss in 2024. This improvement was primarily due to the increase in collaboration and license revenue. The company's cash and cash equivalents stood at $137.5 million as of December 31, 2025. In the first quarter of 2026, Xilio closed a follow-on offering of prefunded warrants, generating net proceeds of approximately $37.3 million, and received a $5.0 million development milestone payment from AbbVie. The company anticipates that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements through the end of 2027.

Operationally, Xilio Therapeutics is focused on advancing its pipeline of masked immuno-oncology therapies. Key strategic goals include submitting an IND application for XTX501 in mid-2026 and initiating a Phase 1 trial in the second half of the year, rapidly advancing its wholly-owned masked T cell engager programs targeting PSMA/STEAP1 and CLDN18.2 into IND-enabling studies with IND applications planned for 2027, and continuing to advance efarindodekin alfa through its ongoing Phase 2 clinical trial to enable delivery of an option data package to Gilead in the first half of 2027. As of February 28, 2026, the company had 76 full-time employees, with 54 engaged in research and development activities.

About Xilio Therapeutics, Inc.

Xilio Therapeutics is a biotech company developing tumor-activated immuno-oncology therapies that localize immune responses within the tumor microenvironment to enhance efficacy and reduce systemic toxicity. Its pipeline includes antibody, cytokine, and T cell engager candidates, leveraging proprietary masking platforms. The company focuses on innovative, highly selective treatments for solid tumors, with collaborations and a strong intellectual property portfolio supporting its mission to improve cancer outcomes.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-K Filings

A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.

Key points about the 10-K:

  • Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
  • Content: It includes:
    • Detailed financial statements audited by an independent accounting firm
    • Management's Discussion and Analysis (MD&A) of financial condition and results
    • Description of the company's business, properties, and legal proceedings
    • Risk factors and market risks
    • Executive compensation and corporate governance information
  • Importance: Considered the most comprehensive and important document a public company files with the SEC.
  • Length: Often exceeds 100 pages due to its extensive and detailed nature.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.